Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD L LAIN

Allopathic & Osteopathic Physicians Dermatology

NPI
1124079306
CMS profile
6301
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$539,173.45

530 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 11; records 151–200 of 530 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD L LAIN

NPI 1124079306 · CMS profile ID 6301

Allopathic & Osteopathic Physicians / Dermatology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 11; records 151–200 of 530 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124079306?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD L LAIN, NPI 1124079306, CMS profile ID 6301. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 11; records 151–200 of 530 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124079306?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EDWARD L LAIN, NPI 1124079306, CMS profile ID 6301. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 11; records 151–200 of 530 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124079306?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EDWARD L LAIN, NPI 1124079306, CMS profile ID 6301, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 11; records 151–200 of 530 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124079306?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

530 matching records · $539,173.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 530 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 530.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $29.4609/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152639153 CMS
ABBVIE INC. $17.5009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104129578 CMS
Arcutis Biotherapeutics, Inc. $373.9509/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121044975 CMS
Incyte Corporation $1,600.0009/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141314907 CMS
Lilly USA, LLC $26.9209/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136167374 CMS
Galderma Laboratories, L.P. $7.9408/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311075 CMS
Galderma Laboratories, L.P. $1.1408/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311073 CMS
Arcutis Biotherapeutics, Inc. $750.0008/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121044947 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $1,500.0008/21/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153808317 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.8508/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153808269 CMS
Biofrontera Inc. $850.0008/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136601932 CMS
Incyte Corporation $149.5008/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169685 CMS
Incyte Corporation $343.9608/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169689 CMS
Incyte Corporation $13.2108/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169693 CMS
Incyte Corporation $59.4608/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169703 CMS
Incyte Corporation $13.2108/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169709 CMS
Incyte Corporation $55.3108/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169895 CMS
Incyte Corporation $8,400.0008/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169905 CMS
UCB, Inc. $24.7408/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143284357 CMS
UCB, Inc. $45.1408/16/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155583341 CMS
UCB, Inc. $45.1508/16/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155583343 CMS
UCB, Inc. $51.7208/16/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155583345 CMS
UCB, Inc. $60.5308/16/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155583347 CMS
UCB, Inc. $133.2008/16/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155583349 CMS
UCB, Inc. $255.4808/16/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155583351 CMS
UCB, Inc. $257.6608/16/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155583353 CMS
Amgen Inc. $13.4808/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117304068 CMS
Galderma Laboratories, L.P. $1.2308/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311071 CMS
Incyte Corporation $219.0008/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169687 CMS
Incyte Corporation $338.4608/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141169691 CMS
Lilly USA, LLC $1,200.0008/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136154878 CMS
Almirall LLC $14,000.0008/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120641344 CMS
ABBVIE INC. $7.0808/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104129576 CMS
Incyte Corporation $1,050.0008/13/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141241378 CMS
LEO Pharma Inc. $27.7408/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152639151 CMS
PFIZER INC. $6.5108/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131851663 CMS
UCB, Inc. $2,075.0008/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143284353 CMS
Galderma Laboratories, L.P. $13.5408/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145311069 CMS
Incyte Corporation $10,000.0008/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141272942 CMS
Regeneron Healthcare Solutions, Inc. $955.0008/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114094857 CMS
Arcutis Biotherapeutics, Inc. $5.3508/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121044943 CMS
Lilly USA, LLC $25.0308/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136149728 CMS
UCB, Inc. $18.2808/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143284340 CMS
UCB, Inc. $2,075.0008/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143284344 CMS
UCB, Inc. $5,500.0008/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143284349 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.4407/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1153808305 CMS
Almirall LLC $1,200.0007/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120641338 CMS
Janssen Biotech, Inc. $15.6907/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078691971 CMS
Lilly USA, LLC $23.9507/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136149726 CMS
UCB, Inc. $2,075.0007/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143284336 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $248,989.54 333
PY2020 $132,676.17 148
PY2021 $159,541.20 208
PY2022 $321,340.92 355
PY2023 $515,869.38 535
PY2024 $539,173.45 530
PY2025 $629,999.43 555

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $27,129.42 6
PY2025 Principal investigator $1,018,334.09 168
PY2024 Recipient $83,492.49 4
PY2024 Principal investigator $812,640.42 213
PY2023 Principal investigator $847,983.34 225
PY2022 Recipient $3,095.32 11
PY2022 Principal investigator $2,197,912.59 171
PY2021 Recipient $3,481.87 1
PY2021 Principal investigator $1,457,384.75 112
PY2020 Recipient $13,272.52 11
PY2020 Principal investigator $1,246,211.91 128
PY2019 Recipient $74,533.35 60
PY2019 Principal investigator $1,861,865.07 102

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

174 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $916.68 12/31/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534987
Principal investigator 1 ABBVIE INC. $32,612.93 12/31/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Multicenter, Blinded, Randomized, Parallel-Group, Comparator-Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid-Face Soft Tissue Augmentation No dispute reported 06/30/2026 1202534989
Principal investigator 1 ABBVIE INC. $2,177.82 12/31/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX in Subjects for Treatment of Glabellar Lines (GL) No dispute reported 06/30/2026 1202534991
Principal investigator 1 Biofrontera Inc. $17,013.50 12/22/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907819
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 12/22/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175375367
Principal investigator 1 ABBVIE INC. $4,388.40 12/17/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202531018
Principal investigator 1 ABBVIE INC. $400.00 12/11/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202530228
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,040.00 12/10/2025 Non-covered Recipient Entity
PFLUGERVILLE DERM CLIN REA CEN
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232947188
Principal investigator 1 Incyte Corporation $40.00 12/05/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504173
Principal investigator 1 Incyte Corporation $40.00 12/05/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504177
Principal investigator 1 Incyte Corporation $43.00 12/05/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504195
Principal investigator 1 Incyte Corporation $43.00 12/05/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504198
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504170
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504181
Principal investigator 1 Incyte Corporation $34.35 12/01/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504191
Principal investigator 1 Biofrontera Inc. $13,967.50 11/27/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907753
Principal investigator 1 Biofrontera Inc. $12,818.85 11/27/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907757
Principal investigator 1 Eli Lilly and Company $4,903.00 11/25/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187877129
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $310.50 11/19/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430892
Principal investigator 1 ABBVIE INC. $2,701.20 11/13/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524069
Principal investigator 1 ABBVIE INC. $36,533.60 11/13/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202524071
Principal investigator 1 Incyte Corporation $2,321.65 11/06/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
An Open-Label, Phase 2, Safety, and Efficacy Study of Ruxolitinib Cream in Participants With Genital Vitiligo No dispute reported 06/30/2026 1240504165
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 11/03/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375274
Recipient Nielsen BioSciences, Inc. $26,518.41 10/30/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1223438117
Principal investigator 1 PFIZER INC. $2,214.00 10/29/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228742094
Principal investigator 1 Vanda Pharmaceuticals Inc. $100.00 10/28/2025 Non-covered Recipient Entity
PFLUGERVILLE DERM CLIN REA CEN
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946790
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,730.00 10/28/2025 Non-covered Recipient Entity
PFLUGERVILLE DERM CLIN REA CEN
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946794
Principal investigator 1 Biofrontera Inc. $583.25 10/24/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907714
Principal investigator 1 Biofrontera Inc. $665.13 10/24/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907716
Principal investigator 1 Incyte Corporation $245.30 10/22/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240504201
Principal investigator 1 ABBVIE INC. $36,117.00 10/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202517213
Principal investigator 1 ABBVIE INC. $2,701.20 10/15/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516913
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,085.00 10/15/2025 Non-covered Recipient Entity
PFLUGERVILLE DERM CLIN REA CEN
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946586
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,000.00 10/15/2025 Non-covered Recipient Entity
PFLUGERVILLE DERM CLIN REA CEN
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946589
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,328.75 10/10/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430890
Principal investigator 1 Incyte Corporation $2,049.00 10/08/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504185
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,050.23 10/08/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL RESEARCH CENTER INC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190307313
Recipient ABBVIE INC. $53.69 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399508
Recipient ABBVIE INC. $21.48 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399512
Recipient ABBVIE INC. $125.35 10/03/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399497
Recipient ABBVIE INC. $123.49 10/03/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399501
Recipient ABBVIE INC. $287.00 10/03/2025 Covered Recipient Physician A Study To Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants with Atrophic Acne Scars No dispute reported 06/30/2026 1202399504
Principal investigator 1 PFIZER INC. $1,295.33 09/26/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228769832
Principal investigator 1 PFIZER INC. $14,858.85 09/24/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228758485
Principal investigator 1 ABBVIE INC. $31,729.65 09/19/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202511656
Principal investigator 1 PFIZER INC. $2,214.00 09/19/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228757967
Principal investigator 1 ABBVIE INC. $2,701.20 09/18/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511482
Principal investigator 1 ABBVIE INC. $500.40 09/17/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511198
Principal investigator 1 PFIZER INC. $2,094.53 09/12/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228770454
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,305.00 09/12/2025 Non-covered Recipient Entity
PFLUGERVILLE DERM CLIN REA CEN
AN OPEN LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY AND EFFICACY OF TRICHOSTATIN A IN PATIENTS WITH MILD TO SEVERE ONYCHOMYCOSIS No dispute reported 06/30/2026 1232946378
Principal investigator 1 Incyte Corporation $1,425.00 09/10/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504132
Principal investigator 1 Incyte Corporation $100.00 09/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504093
Principal investigator 1 Incyte Corporation $86.00 09/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504156
Principal investigator 1 PFIZER INC. $444.90 08/23/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228768057
Principal investigator 1 ABBVIE INC. $12,492.00 08/14/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504913
Principal investigator 1 ABBVIE INC. $96,875.25 08/14/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202504915
Principal investigator 1 Incyte Corporation $10.60 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504105
Principal investigator 1 Incyte Corporation $62.27 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504113
Principal investigator 1 Incyte Corporation $135.40 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504117
Principal investigator 1 Incyte Corporation $32.36 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504121
Principal investigator 1 Incyte Corporation $49.36 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504125
Principal investigator 1 Incyte Corporation $54.76 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504129
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504137
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504141
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504144
Principal investigator 1 Incyte Corporation $32.88 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504149
Principal investigator 1 Incyte Corporation $45.80 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504151
Principal investigator 1 Incyte Corporation $59.13 08/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504161
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/04/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283691
Principal investigator 1 Janssen Research & Development, LLC $1,683.00 08/04/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175375360
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 08/01/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375347
Principal investigator 1 ABBVIE INC. $74.40 07/29/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500326
Principal investigator 1 PFIZER INC. $2,299.73 07/29/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764041
Principal investigator 1 ABBVIE INC. $62.38 07/18/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202498908
Principal investigator 1 Incyte Corporation $50.00 07/18/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504097
Principal investigator 1 Incyte Corporation $43.00 07/18/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504109
Principal investigator 1 ABBVIE INC. $226,893.60 07/17/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202498594
Principal investigator 1 PFIZER INC. $1,136.03 07/17/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228785865
Principal investigator 1 ABBVIE INC. $13,842.60 07/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498378
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,328.75 07/15/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430884
Principal investigator 1 Incyte Corporation $1,425.00 07/09/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504101
Principal investigator 1 Biofrontera Inc. $77.28 07/07/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
OPEN-LABEL PHASE I STUDY TO EVALUATE THE PHARMACOKINETICS OF 5-AMINOLEVULINIC ACID AND PROTOPORPHYRIN IX IN HUMAN PLASMA UNDER MAXIMAL USE CONDITIONS AFTER TOPICAL APPLICATION OF 3 TUBES OF BF-200 ALA TO A TREATMENT FIELD OF 240 CM2 FOR PHOTODYNAMIC THERAPY (PDT) IN SUBJECTS SUFFERING FROM ACTINIC KERATOSIS IN THE PERIPHERY No dispute reported 06/30/2026 1208907538
Principal investigator 1 ABBVIE INC. $537.60 07/02/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202494905
Principal investigator 1 Incyte Corporation $59.13 07/01/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240476508
Principal investigator 1 Incyte Corporation $24.30 07/01/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240476513
Principal investigator 1 Biofrontera Inc. $8.40 06/25/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907501
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,000.00 06/24/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246430862
Principal investigator 1 ABBVIE INC. $49,551.75 06/17/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202491853
Principal investigator 1 ABBVIE INC. $15,376.80 06/12/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491317
Principal investigator 1 Incyte Corporation $1,425.00 06/11/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504054
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 06/09/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175375300
Principal investigator 1 Eli Lilly and Company $901.25 06/05/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875279
Principal investigator 1 Incyte Corporation $34.35 06/03/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240476495
Principal investigator 1 Incyte Corporation $2.43 06/03/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240476501
Principal investigator 1 Incyte Corporation $16.18 06/03/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240476505
Principal investigator 1 Janssen Research & Development, LLC $79.73 05/30/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375354
Principal investigator 1 Janssen Research & Development, LLC $2,714.00 05/26/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375321
Principal investigator 1 ABBVIE INC. $889.20 05/22/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485953
Principal investigator 1 ABBVIE INC. $20,942.40 05/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485369
Principal investigator 1 PFIZER INC. $1,059.08 05/16/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228764368
Principal investigator 1 Janssen Research & Development, LLC $79.73 05/01/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375286
Principal investigator 1 Janssen Research & Development, LLC $527.46 05/01/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375315
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/01/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375338
Principal investigator 1 ABBVIE INC. $2,274.00 04/24/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage No dispute reported 06/30/2026 1202478955
Principal investigator 1 Incyte Corporation $43.00 04/23/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504034
Principal investigator 1 Incyte Corporation $50.00 04/23/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504038
Principal investigator 1 ABBVIE INC. $15,346.20 04/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476905
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 04/14/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226087113
Principal investigator 1 Galderma Laboratories, L.P. $500.00 04/11/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Assess Aesthetic Improvement and Onset of QM1114-DP Treatment Effect in Subjects With Moderate to Severe Glabellar Lines No dispute reported 06/30/2026 1234514147
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,025.00 04/11/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430876
Principal investigator 1 Incyte Corporation $1,425.00 04/09/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504030
Principal investigator 1 Incyte Corporation $43.00 04/09/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504046
Principal investigator 1 Incyte Corporation $75.00 04/09/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504050
Principal investigator 1 Incyte Corporation $50.00 04/09/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504074
Principal investigator 1 PFIZER INC. $1,519.43 04/09/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228778757
Principal investigator 1 Janssen Research & Development, LLC $439.19 04/07/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375265
Principal investigator 1 ABBVIE INC. $960.30 04/03/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage No dispute reported 06/30/2026 1202470545
Principal investigator 1 Biofrontera Inc. $1,982.97 04/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907409
Principal investigator 1 Biofrontera Inc. $1,702.56 04/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS No dispute reported 06/30/2026 1208907412
Principal investigator 1 Biofrontera Inc. $2,384.50 04/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907417
Principal investigator 1 Biofrontera Inc. $1,770.00 04/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907422
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504042
Principal investigator 1 Incyte Corporation $4.86 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504058
Principal investigator 1 Incyte Corporation $24.68 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504062
Principal investigator 1 Incyte Corporation $16.18 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504066
Principal investigator 1 Incyte Corporation $0.62 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504070
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504078
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504083
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504085
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504088
Principal investigator 1 ABBVIE INC. $426.00 03/26/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202466247
Principal investigator 1 Eli Lilly and Company $1,084.80 03/25/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187874823
Principal investigator 1 Janssen Research & Development, LLC $1,459.00 03/21/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375308
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $209.25 03/21/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430874
Principal investigator 1 ABBVIE INC. $47,295.45 03/20/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY
A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage No dispute reported 06/30/2026 1202464922
Principal investigator 1 ABBVIE INC. $47,295.45 03/20/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
C24-AD101 - A Multi-Site Study to Assess the Efficacy and Tolerability Of Exosomes in Females with Moderate to Severe Overall Facial Photodamage No dispute reported 06/30/2026 1202465227
Principal investigator 1 ABBVIE INC. $852.00 03/14/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463885
Principal investigator 1 ABBVIE INC. $16,764.00 03/13/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463576
Principal investigator 1 Incyte Corporation $1,569.00 03/12/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503978
Principal investigator 1 Janssen Research & Development, LLC $1,995.00 03/06/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175375293
Principal investigator 1 PFIZER INC. $4,326.09 03/04/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228719525
Principal investigator 1 Incyte Corporation $2.43 03/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503996
Principal investigator 1 Incyte Corporation $11.45 03/03/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504001
Principal investigator 1 Janssen Research & Development, LLC $3,105.18 03/03/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283707
Principal investigator 1 Biofrontera Inc. $1,500.00 02/28/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A NON-RANODMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BF-200 ALA (AMELUZ) AND BF-RHODOLED XL IN THE EXPANDED FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS ON THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY (PDT) No dispute reported 06/30/2026 1208907370
Principal investigator 1 Amgen Inc. $2,750.00 02/22/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246639487
Principal investigator 1 Eli Lilly and Company $6,094.00 02/18/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880871
Principal investigator 1 ABBVIE INC. $26,796.60 02/13/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202451409
Principal investigator 1 PFIZER INC. $5,890.88 02/11/2025 Non-covered Recipient Entity
Pflugerville Dermatology Clinical Research Center Inc dba Austin Institute for Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228748957
Principal investigator 1 Incyte Corporation $172.00 02/07/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503965
Principal investigator 1 Incyte Corporation $250.00 02/07/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503968
Principal investigator 1 Incyte Corporation $75.00 02/07/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504021
Principal investigator 1 Janssen Research & Development, LLC $2,051.00 02/07/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL R ESEARCH CENTER INC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175375331
Principal investigator 1 Almirall LLC $50.00 02/05/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc.
Tirbanibulin in superficial BCC (sBCC). Interventional, 2 arms, prospective study No dispute reported 06/30/2026 1243871668
Principal investigator 1 Janssen Research & Development, LLC $224.36 02/05/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283668
Principal investigator 1 Eli Lilly and Company $2,302.00 02/04/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187875531
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,025.00 02/04/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430866
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,373.88 02/01/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL RESEARCH CENTER INC
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190307503
Principal investigator 1 Incyte Corporation $5,000.00 01/24/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504013
Principal investigator 1 Almirall LLC $69.00 01/22/2025 Non-covered Recipient Entity
Austin Institute for Clinical Research, Inc.
Tirbanibulin in superficial BCC (sBCC). Interventional, 2 arms, prospective study No dispute reported 06/30/2026 1243871670
Principal investigator 1 Janssen Research & Development, LLC $3,105.18 01/20/2025 Non-covered Recipient Entity
Austin Inst For Clinic Rsrch
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175283662
Principal investigator 1 ABBVIE INC. $30,514.80 01/16/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202439429
Principal investigator 1 Biofrontera Inc. $6,655.11 01/15/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH INC
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907270
Principal investigator 1 Incyte Corporation $1,557.00 01/15/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503961
Principal investigator 1 Incyte Corporation $1,517.00 01/15/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503973
Principal investigator 1 ABBVIE INC. $1,582.80 01/09/2025 Non-covered Recipient Entity
PFLUGERVILLE DERMATOLOGY CLINICAL
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202437691
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503982
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503985
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503988
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240503992
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504005
Principal investigator 1 Incyte Corporation $5.38 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504009
Principal investigator 1 Incyte Corporation $201.40 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504017
Principal investigator 1 Incyte Corporation $21.20 01/02/2025 Non-covered Recipient Entity
AUSTIN INSTITUTE FOR CLINICAL RESEARCH AICR PFLUGERVILLE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240504026